Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026906 | 1.00 | MAPT (0.49) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL9247642 | 0.84 | CA12 (0.68) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL9980893 | 0.82 | CA12 (0.71) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3024474 | 0.82 | CA12 (0.71) | CA1CA2CA12CA7CA9 | |
| SCHEMBL18797967 | 0.81 | MAPT (0.49) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL4440602 | 0.80 | MAPT (0.46) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL4708760 | 0.80 | CES2 (0.50) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL1172246 | 0.80 | TSHR (0.59) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL3026427 | 0.80 | TSHR (0.59) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL1966274 | 0.80 | TSHR (0.59) | MAPTCA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751087-B1 | LEVODOPA DERIVATIVES, AND COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-08-05 | — | — | US | claimed |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-05-28 | — | — | US | claimed |
| US-7534813-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-7342131-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-03-11 | — | — | US | claimed |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | WILSHIRE PHARMACEUTICALS, INC. | 2005-12-22 | — | — | US | claimed |
| EP-1751087-B1 | LEVODOPA DERIVATIVES, AND COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7534813-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080070984-A1 | Compositions and Methods of Treating Schizophrenia | XENOPORT, INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008034087-A2 | TREATING SCHIZOPHRENIA WITH COMBINATIONS OF LEVODOPA AND AN ANTIPSYCHOTIC AGENT | XENOPORT, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7342131-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | WILSHIRE PHARMACEUTICALS, INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | MAPT 1341/4885CA1 3469/4885CA2 4601/4885 |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | MAPT 1341/4885CA1 3469/4885CA2 4601/4885 |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | MAPT 1341/4885CA1 3469/4885CA2 4601/4885 |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | MAPT 1341/4885CA1 3469/4885CA2 4601/4885 |
| US-20080070984-A1 | Compositions and Methods of Treating Schizophrenia | COMT, CHAT, SLC6A3 | MAPT 287/4885CA1 1101/4885CA2 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.